Nuclear Medicine Procedures for Treatment Evaluation and Administration

Referencias bibliográficas

• Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, Wilhelm K, Biersack HJ, Ezziddin S (2010) The significance of 99 mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med 51(8):1206–1212
• Ahmadzadehfar H, Muckle M, Sabet A, Wilhelm K, Kuhl C, Biermann K, Haslerud T, Biersack HJ, Ezziddin S (2011) The significance of bremsstrahlung SPECT/CT after yttrium-90 radioembolization treatment in the prediction of extrahepatic side effects. Eur J Nucl Med Mol Imaging 39:309–315
• Ahmadzadehfar H, Sabet A, Meyer C, Habibi E, Biersack HJ, Ezziddin S (2012) The importance of tc-MAA SPECT/CT for therapy planning of radioembolization in a patient treated with bevacizumab. Clin Nucl Med 37(11):1129–1130
• Bagni O, D’Arienzo M, Chiaramida P, Chiacchiararelli L, Cannas P, D’Agostini A, Cianni R, Salvatori R, Scopinaro F (2012) 90Y-PET for the assessment of microsphere biodistribution after selective internal radiotherapy. Nucl Med Commun 33(2):198–204
• Bilbao JI, Garrastachu P, Herráiz MJ, Rodríguez M, Inarrairaegui M, Rodríguez J, Hernández C, de la Cuesta AM, Arbizu J, Sangro B (2010) Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors. Cardiovasc Interv Radiol 33(3):523–531
• Campbell JM, Wong CO, Muzik O, Marples B, Joiner M, Burmeister J (2009) Early dose response to yttrium-90 microsphere treatment of metastatic liver cancer by a patient-specific method using single photon emission computed tomography and positron emission tomography. Int J Radiat Oncol Biol Phys 74(1):313–320
• Carretero C, Munoz-Navas M, Betes M, Angos R, Subtil JC, Fernandez-Urien I, De la Riva S, Sola J, Bilbao JI, de Luis E (2007) Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol 102(6):1216–1220
• Covey AM, Brody LA, Maluccio MA, Getrajdman GI, Brown KT (2002) Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiology 224(2):542–547
• Cremonesi M, Ferrari M, Bartolomei M, Orsi F, Bonomo G, Aricò D, Mallia A, De Cicco C, Pedroli G, Paganelli G (2008) Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment. Eur J Nucl Med Mol Imaging 35(11):2088–2096
• D’Arienzo M, Chiaramida P, Chiacchiararelli L, Coniglio A, Cianni R, Salvatori R, Ruzza A, Scopinaro F, Bagni O (2012) 90Y PET-based dosimetry after selective internal radiotherapy treatments. Nucl Med Commun 33(6):633–640
• Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J, Hendler AL, Goin JE (2000) Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 41(10):1673–1681
• Even-Sapir E, Keidar Z, Bar-Shalom R (2009) Hybrid imaging (SPECT/CT and PET/CT)–improving the diagnostic accuracy of functional/metabolic and anatomic imaging. Sem Nucl Med 39:264–275
• Fabbri C, Sarti G, Cremonesi M, Ferrari M, Dia AD, Agostini M, Botta F, Paganelli G (2009) Quantitative analysis of 90Y bremsstrahlung SPECT-CT images for application to 3D patient-specific dosimetry. Cancer Biother Radiopharm 24(1):145–154
• Flamen P, Vanderlinden B, Delatte P, Ghanem G, Ameye L, Van Den Eynde M, Hendlisz A (2008) Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with yttrium-90 labeled resin microspheres. Phys Med Biol 53(22):6591–6603
• Ford KW (1955) Predicted 0+ level in 40Zr90. Phys Rev 98:1516–1517
• Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, Poree P, Clement B, Raoul JL, Boucher E (2012) Dosimetry based on 99 mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med 53(2):255–263
• Garin E, Rolland Y, Lenoir L, Pracht M, Mesbah H, Poree P, Laffont S, Clement B, Raoul JL, Boucher E (2011) Utility of quantitative tc-MAA SPECT/CT for yttrium-labelled microsphere treatment planning: calculating vascularized hepatic volume and dosimetric approach. Int J Mol Imaging. doi:10.1155/2011/398051
• Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, Brans B, Lambert B, Konijnenberg M, Borson-Chazot F et al (2011) EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 38(7):1393–1406
• Gulec SA, Mesoloras G, Dezarn WA, McNeillie P, Kennedy AS (2007) Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med 5:15
• Gulec S, Sztejnberg M, Siegel J (2010) Hepatic structural dosimetry in 90Y microsphere treatment: a monte carlo modeling approach based on lobular microanatomy. J Nucl Med 51:301–310
• Gupta A, Gill A, Shrikanthan S, Srinivas S (2012) Nontargeted Y-90 microsphere radioembolization to duodenum visualized on Y-90 PET/CT and bremsstrahlung SPECT/CT. Clin Nucl Med 37:98–99
• Hamami ME, Poeppel TD, Müller S, Heusner T, Bockisch A, Hilgard P, Antoch G (2009) SPECT/CT with 99 mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. J Nucl Med 50:688–692
• Haug AR, Heinemann V, Bruns CJ, Hoffmann R, Jakobs T, Bartenstein P, Hacker M (2011) 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging 38:1037–1045
• Ho S, Lau W, Leung T, Chan M, Ngar Y, Johnson P, Li A (1996) Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med Mol Imaging 23:947–952
• Jha AK, Zade AA, Rangarajan V, Purandare N, Shah SA, Agrawal A, Kulkarni SS, Shetty N (2012) Comparative analysis of hepatopulmonary shunt obtained from pretherapy 99 mTc MAA scintigraphy and post-therapy 90Y bremsstrahlung imaging in 90Y microsphere therapy. Nucl Med Commun 33:486–490
• Kao YH, Tan EH, Ng CE, Goh SW (2011) Yttrium-90 time-of-flight PET/CT is superior to bremsstrahlung SPECT/CT for postradioembolization imaging of microsphere biodistribution. Clin Nucl Med 36(12):186–187
• Kao YH, Tan AEH, Burgmans MC, Irani FG, Khoo LS, Lo RHG, Tay KH, Tan BS, Chow PKH, Ng DCE (2012) Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization. J Nucl Med 53(4):559–566
• Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A, Espat J, Bilbao JI, Sharma RA (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68(1):13–23
• Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, Garafalo M, Liu D, Coldwell D, Savin M et al (2009) Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 74(5):1494–1500
• Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R (2012) Radioembolization for the treatment of liver tumors: general principles. Am J Clin Oncol 35(1):91–99
• Knesaurek K, Machac J, Muzinic M, DaCosta M, Zhang Z, Heiba S (2010) Quantitative comparison of yttrium-90 (90Y)-microspheres and technetium-99 m (99 mTc)-macroaggregated albumin SPECT images for planning 90Y therapy of liver cancer. Technol Cancer Res Treat 9(3):253–262
• Lambert B, Mertens J, Sturm EJ, Stienaers S, Defreyne L, D’Asseler Y (2010) 99 mTc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with 90Y microspheres. Eur J Nucl Med Mol Imaging 37(12):2328–2333
• Lau W, Leung T, Ho S, Chan M, Leung N, Lin J, Metreweli C, Li A (1994) Diagnostic pharmaco-scintigraphy with hepatic intraarterial technetium-99m macroaggregated albumin in the determination of tumour to non-tumour uptake ratio in hepatocellular carcinoma. Br J Radiol 67(794):136–139
• Lau WY, Kennedy AS, Kim YH, Lai HK, Lee RC, Leung TW, Liu CS, Salem R, Sangro B, Shuter B et al (2012) Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 82(1):401–407
• Lenoir L, Edeline J, Rolland Y, Pracht M, Raoul JL, Ardisson V, Bourguet P, Clement B, Boucher E, Garin E (2012) Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. Eur J Nucl Med Mol Imaging 39(5):872–880
• Leong QM, Lai HK, Lo RG, Teo TK, Goh A, Chow PK (2009) Radiation dermatitis following radioembolization for hepatocellular carcinoma: a case for prophylactic embolization of a patent falciform artery. J Vasc Interv Radiol 20(6):833–836
• Leung WT, Lau WY, Ho SK, Chan M, Leung NW, Lin J, Metreweli C, Johnson PJ, Li AK (1994) Measuring lung shunting in hepatocellular carcinoma with intrahepatic-arterial technetium-99m macroaggregated albumin. J Nucl Med 35(1):70–73
• Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, Metreweli C, Johnson PJ, Li AK (1995) Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 33(4):919–924
• Lhommel R, Goffette P, Van den Eynde M, Jamar F, Pauwels S, Bilbao JI, Walrand S (2009) Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. Eur J Nucl Med Mol Imaging 36(10):1696
• Lhommel R, van Elmbt L, Goffette P, Van den Eynde M, Jamar F, Pauwels S, Walrand S (2010) Feasibility of 90 Y TOF PET-based dosimetry in liver metastasis therapy using SIR-spheres. Eur J Nucl Med Mol Imaging 37(9):1654–1662
• Maziere B, Loc’h C, Steinling M, Comar D (1986) Stable labelling of serum albumin microspheres with gallium-68. Int J Radiat Appl Instrum Part A Appl Radiat Isot 37(4):360–361
• Murthy R, Nunez R, Szklaruk J, Erwin W, Madoff DC, Gupta S, Ahrar K, Wallace MJ, Cohen A, Coldwell DM (2005) Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 25(Suppl 1):S41–S55
• Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, Omary RA, Salem R (2009) Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 20(9):1121–1130
• Rodríguez-Fraile M, Arbizu J, Iñarrairaegui M, Martí-Climent J, Quincoces G, Garrastachu P, Domínguez I, Peñuelas I, Sangro B, Richter J (2008) Evaluation of 99mTc-MAA SPECT as a biomarker of liver tumor response to radioembolization with 90-yttrium. Eur J Nucl Med Mol Imaging 35(Suppl 2):S278
• Rong X, Du Y, Frey EC (2012a) A method for energy window optimization for quantitative tasks that includes the effects of model-mismatch on bias: application to Y-90 bremsstrahlung SPECT imaging. Phys Med Biol 57:3711–3725
• Rong X, Du Y, Ljungberg M, Rault E, Vandenberghe S, Frey EC (2012b) Development and evaluation of an improved quantitative 90Y bremsstrahlung SPECT method. Med Phys 39:2346–2358
• Sabet A, Ahmadzadehfar H, Muckle M, Haslerud T, Wilhelm K, Biersack HJ, Ezziddin S (2011) Significance of oral administration of sodium perchlorate in planning liver-directed radioembolization. J Nucl Med 52:1063–1067
• Salem R, Thurston KG (2006) Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 17:1251–1278
• Sánchez-Martínez M, Colantes M, Rodriguez-Fraile M, Dominguez-Prado I, Vidal A, Iñarrairaegui M, Bilbao J, Sangro B, Peñuelas I (2012) Fluorine-18 radiolabelling of SIR-spheres as biodistribution surrogate od radiospheres treatment: in vivo micro-PET and in vitro stability studies. Eur J Nucl Med Mol Imaging 39 (Suppl 2):S-168
• Selwyn R, Avila-Rodriguez M, Converse A, Hampel J, Jaskowiak C, McDermott J, Warner T, Nickles R, Thomadsen B (2007) 18F-labeled resin microspheres as surrogates for 90Y resin microspheres used in the treatment of hepatic tumors: a radiolabeling and PET validation study. Phys Med Biol 52:7397–7408
• Van de Wiele C, Maes A, Brugman E, D’Asseler Y, De Spiegeleer B, Mees G, Stellamans K (2012) SIRT of liver metastases: physiological and pathophysiological considerations. Eur J Nucl Med Mol Imaging 39:1646–1655
• van Elmbt L, Vandenberghe S, Walrand S, Pauwels S, Jamar F (2011) Comparison of yttrium-90 quantitative imaging by TOF and non-TOF PET in a phantom of liver selective internal radiotherapy. Phys Med Biol 56:6759–6777
• Wu SY, Kuo JW, Chang TK, Liu RS, Lee RC, Wang SJ, Lin WJ, Wang HE (2012) Preclinical characterization of 18F-MAA, a novel PET surrogate of 99mTc-MAA. Nucl Med Biol 39:1026–1033
• Yorke ED, Jackson A, Rosenzweig KE, Braban L, Leibel SA, Ling CC (2005) Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 63:672–682
• Yu N, Srinivas SM, Difilippo FP, Shrikanthan S, Levitin A, McLennan G, Spain J, Xia P, Wilkinson A (2013) Lung dose calculation with SPECT/CT for 90Yittrium radioembolization of liver cancer. Int J Radiat Oncol Biol Phys 85:834–839